"Drug Discovery" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The process of finding chemicals for potential therapeutic use.
| Descriptor ID |
D055808
|
| MeSH Number(s) |
E05.295 H01.158.703.007.675 H01.181.466.675
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Discovery".
Below are MeSH descriptors whose meaning is more specific than "Drug Discovery".
This graph shows the total number of publications written about "Drug Discovery" by people in this website by year, and whether "Drug Discovery" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 1 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 4 | 6 |
| 2014 | 0 | 3 | 3 |
| 2015 | 1 | 1 | 2 |
| 2016 | 7 | 4 | 11 |
| 2017 | 73 | 62 | 135 |
| 2018 | 51 | 49 | 100 |
| 2019 | 18 | 22 | 40 |
| 2020 | 21 | 32 | 53 |
| 2021 | 14 | 20 | 34 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Discovery" by people in Profiles.
-
A novel framework integrating AI model and enzymological experiments promotes identification of SARS-CoV-2 3CL protease inhibitors and activity-based probe. Brief Bioinform. 2021 11 05; 22(6).
-
Recent omics-based computational methods for COVID-19 drug discovery and repurposing. Brief Bioinform. 2021 11 05; 22(6).
-
Application of artificial intelligence and machine learning for COVID-19 drug discovery and vaccine design. Brief Bioinform. 2021 11 05; 22(6).
-
Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
-
DNA-encoded chemistry technology yields expedient access to SARS-CoV-2 Mpro inhibitors. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
-
S100A8 may govern hyper-inflammation in severe COVID-19. FASEB J. 2021 09; 35(9):e21798.
-
Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity. Int J Mol Sci. 2021 Aug 22; 22(16).
-
Fluorogenic in vitro activity assay for the main protease Mpro from SARS-CoV-2 and its adaptation to the identification of inhibitors. STAR Protoc. 2021 09 17; 2(3):100793.
-
Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery. Sci Rep. 2021 08 10; 11(1):16174.
-
Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents. IEEE/ACM Trans Comput Biol Bioinform. 2021 Jul-Aug; 18(4):1281-1289.